Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 EarningsZacks Investment Research • 02/13/24
Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatmentMarket Watch • 02/13/24
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapiesCNBC • 02/13/24
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaGlobeNewsWire • 02/12/24
Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health SolutionsBusiness Wire • 02/09/24
Stay Ahead of the Game With Biogen Inc. (BIIB) Q4 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 02/08/24
Biogen Inc. (BIIB) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 02/02/24
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatmentsCNBC • 01/31/24